Biortica Agrimed’s reverse takeover of Bod Science has been further delayed, but a potential stumbling block has been finally removed, it has emerged.
Bod’s administrator, Andrew Barnden, said in an update to the ASX this week that an extraordinary general meeting for the firm’s shareholders to vote on the deal, scheduled for September, has been pushed back to late November.
It is the second time the EGM has been postponed from its original date of mid-2024.
Continue reading...
Last edited by a moderator:
